Public Relations
This page lists 732 references in the Main Healthy Skepticism Library relevant to Public Relations.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL10789
Rosenkilde CE.
Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.
Neurology 2007 Apr 17;68(16):1325
http://www.neurology.org/cgi/content/full/68/16/1325-a
HSL9058
Berlin J, Bruinooge SS, Tannock IF.
Ethics in oncology: consulting for the investment industry.
J Clin Oncol 2007 Feb 1;25(4):444-6
http://www.jco.org/cgi/content/full/25/4/444
HSL6901
Carrie AG, Grymonpre RE, Blandford AA.
Impact of Residence on Prevalence and Intensity of Prescription Drug Use Among Older Adults (November).
Ann Pharmacother 2006 Oct 10
http://www.theannals.com/cgi/reprint/aph.1H338v1
HSL6737
Kees J.
Pharmaceutical Forum: delivering better information, access, prices
e drug 2006 Sep 29
HSL6788
Lassen LC, Thomsen MK.
[Global health--the ethical responsibility of the pharmaceutical industry].
Ugeskr Laeger 2006 Sep 4;168(36):2994-5
HSL6665
Shrank WH, Joseph GJ, Choudhry NK, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL.
Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?
Am J Manag Care 2006 Sep 01;12(9):545-51
http://www.ajmc.com/Article.cfm?ID=3191&CFID=3768231&CFTOKEN=45537093
HSL6538
Cuzzolin L, Atzei A, Fanos V.
Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.
Expert Opin Drug Saf 2006 Sep 01;5(5):703-18
http://www.expertopin.com/doi/abs/10.1517/14740338.5.5.703
HSL6666
Carroll NV, Smith JC, Berringer RA, Oestreich GL.
Evaluation of an automated system for prior authorization: a COX-2 inhibitor example.
Am J Manag Care 2006 Sep 01;12(9):501-8
http://www.ajmc.com/Article.cfm?ID=3187&CFID=3768231&CFTOKEN=45537093
HSL6646
Memory enhancement--a neuroethical dilemma.
Lancet 2006 Aug 19;368(9536):620
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69219-2
HSL6768
Dismissal upheld in HIV drug monopoly claim.
AIDS Policy Law 2006 Aug 11;21(15):7
HSL6751
Ornes L, Hendrix TJ.
Prescription drug re-importation: a balanced look.
J Gerontol Nurs 2006 Aug 01;32(8):15-9
HSL6752
Kripalani S, Henderson LE, Chiu EY, Robertson R, Kolm P, Jacobson TA.
Predictors of medication self-management skill in a low-literacy population.
J Gen Intern Med 2006 Aug 01;21(8):852-6
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2006.00536.x
HSL6808
Wong IC, Basra N, Yeung VW, Cope J.
Supply problems of unlicensed and off-label medicines after discharge.
Arch Dis Child 2006 Aug 01;91(8):686-8
http://adc.bmjjournals.com/cgi/content/full/91/8/686
HSL6200
White C.
Chief medical officer calls for rewards to improve clinical practice
BMJ 2006 Jul 29;33(7561):216
http://bmj.bmjjournals.com/cgi/content/short/333/7561/216-a?etoc%3e
HSL6204
The Practice of Reform in Health, Medicine and Science, 1500-2000
BMJ 2006 Jul 29;333(7561):266
http://bmj.bmjjournals.com/cgi/content/short/333/7561/266-a?etoc%3e
HSL6531
Drug pricing. AHF cautions company over new AIDS drug price.
AIDS Policy Law 2006 Jul 28;21(14):1
HSL6205
Melnikow J, Kuenneth C, Helms LJ, Barnato A, Kuppermann M, Birch S, Nuovo J.
Chemoprevention: Drug pricing and mortality: the case of tamoxifen.
Cancer 2006 Jul 24
Link to source with long URL
HSL6532
Carreyrou J.
Seizures of Canadian drugs rise as Congress, Customs spar.
Wall St J (East Ed) 2006 Jul 24:B1
HSL5991
Roehr B.
Roche’s tiered pricing enables poorer countries to stockpile drugs
BMJ 2006 Jul 8;333(7558):63
http://bmj.bmjjournals.com/cgi/content/short/333/7558/63?etoc
HSL5933
Davis S, Affatato A.
Blunt chest trauma: utility of radiological evaluation and effect on treatment patterns.
Am J Emerg Med 2006 Jul 01;24(4):482-6
http://linkinghub.elsevier.com/retrieve/pii/S0735-6757(06)00071-4
HSL6343
Sonntag A, Matschinger H, Angermeyer MC, Riedel-Heller SG.
Does the context matter? Utilization of sedative drugs in nursing homes - a multilevel analysis
Pharmacopsychiatry. 2006 Jul 01;39(4):142-9
http://www.thieme-connect.com/DOI/DOI?10.1055/s-2006-946704
HSL6397
Wilksch SM, Tiggemann M, Wade TD.
Impact of interactive school-based media literacy lessons for reducing internalization of media ideals in young adolescent girls and boys.
Int J Eat Disord 2006 Jul 01;39(5):385-93
Link to source with long URL
HSL6778
Kesselman I, Elstein D, Israeli A, Chertkoff R, Zimran A.
National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model.
Blood Cells Mol Dis 2006 Jul-Aug 01;37(1):46-9
Link to source with long URL
HSL6805
Kesselheim AS, Fischer MA, Avorn J.
The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Health Aff (Millwood) 2006 Jul-Aug 01;25(4):1095-102
http://content.healthaffairs.org/cgi/content/full/25/4/1095
HSL5955
Mokhiber R, Weissman R.
A New Way For Drug Development?
corp-focus 2006 Jun 30
http://lists.essential.org/pipermail/corp-focus/2006/000244.html
HSL5807
Sutcliffe AG, Wong IC.
Rational prescribing for children.
BMJ 2006 Jun 24;332(7556):1464-5
http://bmj.bmjjournals.com/cgi/content/full/332/7556/1464
HSL5808
Hagan P.
Four in five asthma deaths may be due to long acting beta agonists.
BMJ 2006 Jun 24;332(7556):1467
http://bmj.bmjjournals.com/cgi/content/extract/332/7556/1467-a
HSL5936
Andersen M, Kragstrup J, Sondergaard J.
How conducting a clinical trial affects physicians' guideline adherence and drug preferences.
JAMA 2006 Jun 21;295(23):2759-64
http://jama.ama-assn.org/cgi/content/full/295/23/2759
HSL5937
Psaty BM, Rennie D.
Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry.
JAMA 2006 Jun 21;295(23):2787-90
http://jama.ama-assn.org/cgi/content/full/295/23/2787
HSL5975
Cohen JP.
Cost-effectiveness and resource allocation.
JAMA 2006 Jun 21;295(23):2723
http://jama.ama-assn.org/cgi/content/full/295/23/2723
HSL5721
Tanne JH.
Antipsychotic use among US young people has risen sixfold.
BMJ 2006 Jun 17;332(7555):1407
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1407?etoc
HSL5722
Eaton L.
European agency approves use of fluoxetine for children and teens.
BMJ 2006 Jun 17;332(7555):1407
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1407-a?etoc
HSL6215
Lafolie P.
[Final reply: drug companies must be allowed to make profit].
Lakartidningen 2006 Jun 14-27;103(24-25):1979
HSL5768
Millson DS.
Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?
BMJ 2006 Jun 10;332(7554):1393
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393?etoc
HSL5812
Reenan J.
Rx for physician prescribing practices
Virtual Mentor. 2006; 8: 2006 Jun 1;8(6):359-361
http://www.ama-assn.org/ama/pub/category/16249.html
HSL5813
Finkelstein JA.
Unnecessary antibiotics
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):362-366
http://www.ama-assn.org/ama/pub/category/16250.html
HSL5814
Adair R.
Hidden costs of free samples
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):367-371
http://www.ama-assn.org/ama/pub/category/16251.html
HSL5815
Sierles FS.
The gift-giving influence
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):372-376
http://www.ama-assn.org/ama/pub/category/16252.html
HSL5817
Ruiz JG, Hagenlocker B.
E-prescribing
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):381-386
http://www.ama-assn.org/ama/pub/category/16254.html
HSL5931
Mabasa VH, Ma J.
Effect of a Therapeutic Maximum Allowable Cost (MAC) Program on the Cost and Utilization of Proton Pump Inhibitors in an Employer-Sponsored Drug Plan in Canada.
J Manag Care Pharm 2006 Jun 01;12(5):371-6
HSL5958
Vieira FS, Zucchi P.
[Price differences between generic and innovator medicines in Brazil].
Rev Saude Publica 2006 Jun 01;40(3):444-9
Link to source with long URL
HSL5977
Johnson DH.
Keynote comment: Cancer drug pricing in the USA.
Lancet Oncol 2006 Jun 01;7(6):444-5
http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(06)70702-1
HSL6383
Livesey JE, Chiew YF.
Antimicrobial drug utilisation in Dunedin Hospital, New Zealand, and its association with antimicrobial resistance.
Pathology 2006 Jun 01;38(3):245-8
Link to source with long URL
HSL6614
Westerlund LT, Bjork HT.
Pharmaceutical care in community pharmacies: practice and research in Sweden.
Ann Pharmacother 2006 Jun 01;40(6):1162-9
http://www.theannals.com/cgi/content/full/40/6/1162
HSL5616
Silversides A.
Monitoring the price of new drugs.
CMAJ 2006 May 23;174(11):1548-9
Link to source with long URL
HSL5481
Hitchen L.
Adverse drug reactions result in 250,000 UK admissions a year.
BMJ 2006 May 13;332(7550):1109
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1109
HSL5610
Radley DC, Finkelstein SN, Stafford RS.
Off-label prescribing among office-based physicians.
Arch Intern Med 2006 May 8;166(9):1021-6
http://archinte.ama-assn.org/cgi/content/full/166/9/1021
HSL5127
Tuffs A.
German law to cuts drug costs angers doctors.
BMJ 2006 May 6;332(7549):1051
http://bmj.bmjjournals.com/cgi/content/full/332/7549/1051
HSL2681
Zoutman D E, Ford BD, Bassili AR
Prescription data
Canadian Medical Association Journal 2006 May 01;164(10):1410-1409
HSL5749
Novas C.
What is the bioscience industry doing to address the ethical issues it faces?
PLoS Med 2006 May 01;3(5):e142
Link to source with long URL
HSL6102
Electronic chip fights counterfeiting.
AIDS Patient Care STDS 2006 May 01;20(5):380-1
HSL6114
Ali MH, Kalima P, Maxwell SR.
Failure to implement hospital antimicrobial prescribing guidelines: a comparison of two UK academic centres.
J Antimicrob Chemother 2006 May 01;57(5):959-62
http://jac.oxfordjournals.org/cgi/content/full/57/5/959
HSL6210
Shiwani MH.
Quest of prescribing practice in Pakistan.
J Pak Med Assoc 2006 May 01;56(5):249-50
HSL6328
Williams R, Marion J.
Are drug too expensive in Canada? No
Can Fam Physician 2006 May 01;52:573-6, 578-81
HSL6329
Lexchin J.
Are drugs too expensive in Canada? Yes
Can Fam Physician. 2006 May 01;52:573-6, 578-81
http://www.cfpc.ca/cfp/2006/May/vol52-may-debates-1.asp
HSL5577
Hu A, Chow CM, Dao D, Errett L, Keith M.
Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement.
J Cardiovasc Nurs 2006 May-Jun;21(3):169-75
Link to source with long URL
HSL6105
Grace M.
Ethical marketing.
Br Dent J 2006 Apr 22;200(8):418
http://www.nature.com/doifinder/10.1038/sj.bdj.4813532
HSL5592
Rane A.
[Drug committees should not recommend 'off label' prescriptions].
Lakartidningen 2006 Apr 12-25;103(15-16):1219
HSL5499
Lexchin J.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ 2006 Apr 11;174(8):1120-1
http://www.cmaj.ca/cgi/content/full/174/8/1120
HSL5706
Davis RL, Khoury MJ.
A public health approach to pharmacogenomics and gene-based diagnostic tests.
Pharmacogenomics 2006 Apr 01;7(3):331-7
http://www.futuremedicine.com/doi/abs/10.2217/14622416.7.3.331
HSL5589
Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, Howard R.
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.
BMJ 2006 Apr 1;332(7544):756-61
http://bmj.bmjjournals.com/cgi/content/full/332/7544/756
HSL5747
Sullivan EE.
The propofol controversy.
J Perianesth Nurs 2006 Apr 01;21(2):128-30
http://linkinghub.elsevier.com/retrieve/pii/S1089-9472(06)00046-3
HSL5748
Odom-Forren J.
The propofol debate continues.
J Perianesth Nurs 2006 Apr 01;21(2):77-8
http://linkinghub.elsevier.com/retrieve/pii/S1089-9472(06)00078-5
HSL5934
Cooke CE, Hammerash WJ Jr.
Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
Clin Ther 2006 Apr 01;28(4):591-9
Link to source with long URL
HSL5962
Kline AD.
On complicity theory.
Sci Eng Ethics 2006 Apr 01;12(2):257-64
HSL5980
Klein CA.
Dispensing pharmaceutical samples: a few reminders.
Nurse Pract 2006 Apr 01;31(4):15
Link to source with long URL
HSL6779
Alphs L.
An industry perspective on the NIMH consensus statement on negative symptoms.
Schizophr Bull 2006 Apr 01;32(2):225-30
http://schizophreniabulletin.oxfordjournals.org/cgi/content/full/32/2/225
HSL5583
Bestehorn K, Voller H, Benecke H, Renner H, Karmann B, Wegscheider K.
Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment.
Curr Med Res Opin 2006 Apr;22(4):631-9
Link to source with long URL
HSL5630
Martin A.
Stimulating: prescribing amidst controversy.
Am J Psychiatry 2006 Apr;163(4):574-7
Link to source with long URL
HSL5771
Harvie J.
Rebels with a cause: The constant campaigner
Australian Doctor 2006 Mar 31:20
HSL6809
Unger T.
[Innovation or pseudo-innovation: that is the question].
Med Klin (Munich) 2006 Mar 15;101(3):257-62
HSL5571
Cardarelli R, Licciardone JC, Taylor LG.
A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
BMC Fam Pract 2006 Mar 3;7(13)
http://www.biomedcentral.com/1471-2296/7/13
HSL5359
Jeppsson A.
[Drug development costs are overstated by the industry].
Lakartidningen 2006 Mar 1-7;103(9):663-4
HSL5494
Boyce P.
Restoring wisdom to the practice of psychiatry.
Australas Psychiatry 2006 Mar 01;14(1):3-7
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1665.2006.02241.x
HSL5688
Salerno RA, Lesko LJ.
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Pharmacogenomics J 2006 Mar-Apr 01;6(2):78-81
http://www.nature.com/tpj/journal/v6/n2/abs/6500345a.html
HSL5916
Ruiz JG, Mintzer MJ, Leipzig RM.
The impact of E-learning in medical education.
Acad Med 2006 Mar 01;81(3):207-12
Link to source with long URL
HSL5368
Maclure M, Nguyen A, Carney G, Dormuth C, Roelants H, Ho K, Schneeweiss S.
Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners.
Basic Clin Pharmacol Toxicol 2006 Mar;98(3):243-52
Link to source with long URL
HSL5090
Lenzer J.
US agency launches initiative on better prescribing for hypertension.
BMJ 2006 Feb 18;332(7538):379
http://bmj.bmjjournals.com/cgi/content/full/332/7538/379-a/DC1
HSL5506
Berenson A.
A cancer drug shows promise, at a price that many can't pay.
NY Times (Print) 2006 Feb 15;A1
HSL5425
Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates DW.
Adherence to black box warnings for prescription medications in outpatients.
Arch Intern Med 2006 Feb 13;166(3):338-44
http://archinte.ama-assn.org/cgi/content/full/166/3/338
HSL5289
Flaten O.
[Are children getting the right drugs?]
Tidsskr Nor Laegeforen 2006 Feb 9;126(4):481 2006 Feb 9;126(4):481
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1341354
HSL5273
Andre T, De Gramont A.
[A good cooperation between industry and French medical oncologists]
Bull Cancer. 2006 Feb 01;93(Supp 1):S3-4
Link to source with long URL
HSL5753
Sarek M.
Evident exception in clinical practice not sufficient to break traditional hypothesis.
PLoS Med 2006 Feb 01;3(2):e120
Link to source with long URL
HSL5754
Rickels K.
Consumer advertising can be misleading.
PLoS Med 2006 Feb 01;3(2):e119
Link to source with long URL
HSL5757
Goldstein S.
Is ADHD a growth industry?
J Atten Disord 2006 Feb 01;9(3):461-4
http://jad.sagepub.com/cgi/reprint/9/3/461
HSL5495
Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, Markides K.
Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study.
J Gerontol A Biol Sci Med Sci 2006 Feb;61(2):170-5
http://biomed.gerontologyjournals.org/cgi/content/full/61/2/170
HSL5573
Genuis SK, Genuis SJ.
Exploring the continuum: medical information to effective clinical practice. Paper I: the translation of knowledge into clinical practice.
J Eval Clin Pract 2006 Feb;12(1):49-62
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2753.2005.00609.x
HSL5236
Clarke JT.
Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
CMAJ 2006 Jan 17;174(2):189-90
http://www.cmaj.ca/cgi/content/full/174/2/189
HSL5033
Fuchs J, Hippius M, Schaefer M.
Analysis of German package inserts.
Int J Clin Pharmacol Ther 2006 Jan;44(1):8-13
HSL5434
Wolfson W.
Holding back the tide of antibiotic resistance.
Chem Biol 2006 Jan 01;13(1):1-3
http://linkinghub.elsevier.com/retrieve/pii/S1074-5521(06)00005-6
HSL5652
Lyles A.
Creating alternative incentives for pharmaceutical innovation.
Clin Ther 2006 Jan 01;28(1):126-8
Link to source with long URL
HSL5673
Chan CH.
The pharmaceutical role.
Acad Psychiatry 2006 Jan-Feb 01;30(1):45-7
http://ap.psychiatryonline.org/cgi/content/full/30/1/45
HSL5686
Skiba M.
Strategies for identifying and minimizing medication errors in health care settings.
Health Care Manag (Frederick) 2006 Jan-Mar 01;25(1):70-7
Link to source with long URL
HSL6340
Yoon EY, Davis MM, El-Essawi H, Cabana MD.
FDA labeling status of pediatric medications.
Clin Pediatr (Phila) 2006 Jan-Feb 01;45(1):75-7
HSL5302
Brekke KR, Kuhn M.
Direct to consumer advertising in pharmaceutical markets.
J Health Econ 2006 Jan;25(1):102-30
Link to source with long URL
HSL5346
Windmeijer F, de Laat E, Douven R, Mot E.
Pharmaceutical promotion and GP prescription behaviour.
Health Econ 2006 Jan;15(1):5-18
http://www3.interscience.wiley.com/cgi-bin/abstract/110504860/ABSTRACT
HSL5124
Seeman N, Brown AD.
Remembering Peter Drucker: inspiring the quality revolution in healthcare.
Healthc Q 2006;9(1):50-2,
HSL5399
Dutta-Bergman MJ.
A formative approach to strategic message targeting through soap operas: using selective processing theories.
Health Commun 2006;19(1):11-8
Link to source with long URL
HSL5959
Mitchell TB, Dyer KR, Peay ER.
Patient and physician characteristics in relation to clinical decision making in methadone maintenance treatment.
Subst Use Misuse 2006;41(3):393-404
Link to source with long URL
HSL6496
Sharp RR, Yarborough M.
Informed trust and the financing of biomedical research.
J Law Med Ethics 2006 Sum;34(2):460-4
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1748-720X.2006.00052.x
HSL6570
Datti B, Carter MW.
The effect of direct-to-consumer advertising on prescription drug use by older adults.
Drugs Aging 2006;23(1):71-81
HSL6787
Arden JD, Brensilver PC.
A bitter pill for plaintiffs: obstacles to market theories of causation in prescription drug consumer fraud cases.
Food Drug Law J 2006;61(3):539-46
HSL6794
Roller ST, Voorhees T Jr, Lunkenheimer AK.
Obesity, food marketing and consumer litigation: threat or opportunity?
Food Drug Law J 2006;61(3):419-44
HSL6974
Tonkin AL, Taverner D, Latte J, Doecke C.
The Effect of an Interactive Tutorial on the Prescribing Performance of Senior Medical Students
Med Educ. 2006
HSL5352
Activists lift boycott of Abbott Laboratories.
AIDS Policy Law 2005 Dec 30;21(1):2
HSL4046
Brett AS, Zuger A.
The run on tamiflu--should physicians prescribe on demand?
N Engl J Med 2005 Dec 22;353(25):2636-7
Link to source with long URL
HSL4035
Huang F, Et AL.
The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior
Academic Psychiatry 2005 Dec 1(29):500-501
http://ap.psychiatryonline.org/cgi/content/full/29/5/500
HSL5220
Tuohy N, Paparella S.
Look-alike and sound-alike drugs: errors just waiting to happen.
J Emerg Nurs 2005 Dec;31(6):569-71
http://linkinghub.elsevier.com/retrieve/pii/S0099-1767(05)00437-X
HSL5295
Citrome L, Jaffe A, Levine J, Lindenmayer JP.
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.
J Clin Psychiatry 2005 Dec;66(12):1512-6
http://article.psychiatrist.com/?ContentType=START&ID=10002270
HSL5387
Sims C.
Off-label use of drugs remains a concern for anaesthetists caring for children.
Anaesth Intensive Care 2005 Dec;33(6):824
HSL5590
Zuckerman IH, Hernandez JJ, Gruber-Baldini AL, Hebel JR, Stuart B, Zimmerman S, Magaziner J.
Potentially inappropriate prescribing before and after nursing home admission among patients with and without dementia.
Am J Geriatr Pharmacother 2005 Dec;3(4):246-54
Link to source with long URL
HSL3895
Day M.
How the Media caught Tamiflu
BMJ 2005 Nov 26;331:1277
http://bmj.bmjjournals.com/cgi/content/full/331/7527/1277
HSL5327
Fonzo-Christe C, Herrmann F, Bonnabry P.
Quality assessment of the visits of pharmaceutical company representatives to hospital pharmacists.
Swiss Med Wkly 2005 Nov 19;135(45-46):666-73
Link to source with long URL
HSL5405
Anand G.
Why Genzyme can charge so much for Cerezyme.
Wall St J (East Ed) 2005 Nov 16;A15
HSL5406
Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
Wall St J (East Ed) 2005 Nov 16;A1,
HSL5445
Small DH.
Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?
Expert Opin Emerg Drugs 2005 Nov 01;10(4):817-25
Link to source with long URL
HSL5217
Santell JP, Cousins DD.
Medication errors related to product names.
Jt Comm J Qual Patient Saf 2005 Nov;31(11):649-54
HSL5265
Curtiss FR.
Who Needs XR, LA, SR, XL, ER, or CR?
J Manag Care Pharm 2005 Nov-Dec;11(9):772-3,
HSL5266
Hong SH, Shepherd MD, Scoones D, Wan TT.
Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
J Manag Care Pharm 2005 Nov-Dec;11(9):746-54
HSL5066
Wright J.
Hormone replacement therapy: an example of McKinlay's theory on the seven stages of medical innovation.
J Clin Nurs 2005 Oct;14(9):1090-7
HSL5121
Davidoff F, Batalden P.
Toward stronger evidence on quality improvement. Draft publication guidelines: the beginning of a consensus project.
Qual Saf Health Care 2005 Oct;14(5):319-25
Link to source with long URL
HSL6841
Nyigo VA, Malebo HM.
Drug discovery and developments in developing countries: bottlenecks and way forward.
Tanzan Health Res Bull 2005 Sep 01;7(3):154-8
HSL4223
Verdoux H, Cougnard A, Grolleau S, Begaud B.
Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care.
Schizophr Res 2005 Sep 1;77(1):107-9
http://linkinghub.elsevier.com/retrieve/pii/S0920-9964(05)00066-6
HSL5858
Bell DS, Friedman MA.
E-prescribing and the medicare modernization act of 2003. Paving the on-ramp to fully integrated health information technology?
Health Aff (Millwood) 2005 Sep-Oct 01;24(5):1159-69
http://content.healthaffairs.org/cgi/content/full/24/5/1159
HSL5920
Sittig DF, Krall M, Kaalaas-Sittig J, Ash JS.
Emotional aspects of computer-based provider order entry: a qualitative study.
J Am Med Inform Assoc 2005 Sep-Oct 01;12(5):561-7
http://www.jamia.org/cgi/content/full/12/5/561
HSL3942
Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2(2):16-22
HSL5575
Pandolfini C, Bonati M.
A literature review on off-label drug use in children.
Eur J Pediatr 2005 Sep;164(9):552-8
HSL5073
Krebs J.
PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man.
N Z Med J 2005 Aug 26;118(1221):U1641
HSL4056
Burton B
US drug industry's guidelines on advertising too limited, say critics.
BMJ 2005 Aug 20;331(7514):420
Link to source with long URL
HSL2732
Sharfstein SS.
Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly.
Psychiatric News 2005 Aug 19;40(16):3
http://pn.psychiatryonline.org/cgi/content/full/40/16/3
HSL4177
Miller FG, Wendler D.
Direct-to-consumer advertising and physician prescribing.
JAMA 2005 Aug 10;294(6):678
http://jama.ama-assn.org/cgi/content/full/294/6/678
HSL2484
Smith R.
Curbing the Influence of the Drug Industry: A British View.
PLoS Med 2005 Aug 2;2(9):e241
Link to source with long URL
HSL2472
Kaye KI, Welch SA, Graudins LV, Graudins A, Rotem T, Davis SR, Day RO.
Pethidine in emergency departments: promoting evidence-based prescribing.
Med J Aust 2005 Aug 1;183(3):129-33
http://www.mja.com.au/public/issues/183_03_010805/kay10502_fm.html
HSL4054
Glaxo inks AIDS vaccine deal with nonprofit.
AIDS Read 2005 Aug 01;15(8):391
HSL4214
Frank RG.
Looking for truth in all the wrong places.
Med Care 2005 Aug 01;43(8):751-2
Link to source with long URL
HSL5681
Izzo JL Jr.
Your drug, my drug, or our drugs: how aggressive should we be with antihypertensive therapy?
J Clin Hypertens (Greenwich) 2005 Aug 01;7(8)
Link to source with long URL
HSL2429
Adair RF, Holmgren LR.
Do drug samples influence resident prescribing behavior? A randomized trial.
Am J Med 2005 Aug;118(8):881-4
http://www.amjmed.com/article/PIIS000293430500197X/fulltext
HSL5390
Honebrink A.
Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies.
Expert Opin Emerg Drugs 2005 Aug;10(3):619-41
Link to source with long URL
HSL5852
Bates DW.
Computerized physician order entry and medication errors: finding a balance.
J Biomed Inform 2005 Aug;38(4):259-61
Link to source with long URL
HSL2487
Maxwell SR.
Evidence based prescribing.
BMJ 2005 Jul 30;331(7511):247-8
http://bmj.bmjjournals.com/cgi/content/full/331/7511/247
HSL4198
Mervis J.
Pharma goes to work. Introduction.
Science 2005 Jul 29;309(5735):721
HSL4053
Croll TP, Swanson BZ Jr19th century dentistry.
Advertising trade cards.
J Hist Dent 2005 Jul 01;53(2):62
HSL5658
Senior K.
Neglected diseases: getting less neglected?
Drug Discov Today 2005 Jul 1;10(13):878
Link to source with long URL
HSL5890
Miller RA, Gardner RM, Johnson KB, Hripcsak G.
Clinical decision support and electronic prescribing systems: a time for responsible thought and action.
J Am Med Inform Assoc 2005 Jul-Aug 01;12(4):403-9
http://www.jamia.org/cgi/content/full/12/4/403
HSL2489
Roehr B.
Report argues US should not pay more than rest of world to fight HIV/AIDS
BMJ 2005 Jul;331:256
http://bmj.bmjjournals.com/cgi/content/extract/331/7511/256-b
HSL2490
Burton B.
US governor plans to import cheaper drugs from Australia and New Zealand
BMJ 2005 Jul;331:256.
Link to source with long URL
HSL2645
Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D.
Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program.
Pharmacotherapy 2005 Jul;25(7):924-34
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed
HSL3947
Lenzer J .
What can we learn from medical whistleblowers?
PLoS Med 2005 Jul;2(7):e209
Link to source with long URL
HSL5304
Wertheimer AI, Santella TM.
Counterfeit drugs: defining the problem and finding solutions.
Expert Opin Drug Saf 2005 Jul;4(4):619-22
Link to source with long URL
HSL5915
Rosenbloom ST, Geissbuhler AJ, Dupont WD, Giuse DA, Talbert DA, Tierney WM, Plummer WD, Stead WW, Miller RA.
Effect of CPOE user interface design on user-initiated access to educational and patient information during clinical care.
J Am Med Inform Assoc 2005 Jul-Aug;12(4):458-73
http://www.jamia.org/cgi/content/full/12/4/458
HSL1929
Avorn J.
Torcetrapib and atorvastatin--should marketing drive the research agenda?
N Engl J Med 2005 Jun 23;352(25):2573-6
http://content.nejm.org/cgi/content/extract/352/25/2573
HSL1918
Metherell M.
Lung cancer drugs will cost more
The Sydney Morning Herald 2005 Jun 17
Link to source with long URL
HSL1919
Pear R.
Medicare Officials Insisting on Wider Choices in Drug Benefits
The New York Times 2005 Jun 15
Link to source with long URL
HSL1915
Jackson L.
A marketing breakthrough
Mediawatch ABC Online 2005 Jun 13
http://www.abc.net.au/mediawatch/transcripts/s1390967.htm
HSL1985
Zipkin DA, Steinman MA.
Interactions Between Pharmaceutical Representatives and Doctors in Training: A thematic review.
J Gen Intern Med 2005 Jun 13;20(8):777-86
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.0134.x
HSL1911
Mandel M.
Smokin' family feud: Michele Mandel visits the home of the Kaczmarczyks. He's on a hunger strike because she won't quit smoking
The Toronto Sun 2005 Jun 12
HSL1913
Health Canada to receive FDA award
CNW Telbec 2005 Jun 10
HSL1907
Words to the wise healthcare consumer: Approach with caution
2005 Jun 8
HSL1909
Berenson A.
At Pfizer, the Isolation Increases for a Whistle-Blower: No man is an island. But Peter Rost is getting close.
2005 Jun 8
HSL2388
Henry DA, Kerridge IH, Hill SR, McNeill PM, Doran E, Newby DA, Henderson KM, Maguire J, Stokes BJ, Macdonald GJ, Day RO.
Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience.
Med J Aust 2005 Jun 6;182(11):557-60
http://www.mja.com.au/public/issues/182_11_060605/hen10805_fm.html
HSL1978
Stocks N, Allan J, Mansfield PR.
Management of hyperlipidaemia.
Aust Fam Physician 2005 Jun;34(6):447-53
http://www.racgp.org.au/document.asp?id=17049
HSL4047
Direct-to-consumer advertising: impact on prescribing.
Child Health Alert 2005 Jun;24:5-6
Link to source with long URL
HSL4058
Bateman C.
Government 'encouraging snake-oil salesman' Rath.
S Afr Med J 2005 Jun 01;95(6):372,
Link to source with long URL
HSL4240
Jackson G.
Generic prescribing -- the chaos continues.
Int J Clin Pract 2005 Jun 01;59(6):618
Link to source with long URL
HSL6661
Tobi H, Scheers T, Netjes KA, Mulder EJ, de Bildt A, Minderaa RB.
Drug utilisation by children and adolescents with mental retardation: a population study.
Eur J Clin Pharmacol 2005 Jun 01;61(4):297-302
http://www.springerlink.com/content/r36010x80235t0k5/
HSL2430
Freudenberg N.
Public health advocacy to change corporate practices: implications for health education practice and research.
Health Educ Behav 2005 Jun;32(3):298-319
http://heb.sagepub.com/cgi/reprint/32/3/298
HSL2473
Pouye A, Dia D, Sow PS, Yacouba H, Ndour CT, Soumare M, Ciss M, Moreira Diop T.
[Prescription of morphinics in the management of pain in Dakar teaching hospitals]
Bull Soc Pathol Exot. 2005 Jun;98(2):118-20
Nil
HSL2475
Belongia EA, Knobloch MJ, Kieke BA, Davis JP, Janette C, Besser RE.
Impact of statewide program to promote appropriate antimicrobial drug use.
Emerg Infect Dis 2005 Jun;11(6):912-20
http://www.cdc.gov/ncidod/EID/vol11no06/05-0118.htm
HSL1930
Brodkey AC.
The role of the pharmaceutical industry in teaching psychopharmacology: a growing problem.
Acad Psychiatry 2005 Sum;29(2):222-9
http://ap.psychiatryonline.org/cgi/content/full/29/2/222
HSL1723
Burton B.
Drug chiefs ponder how to improve industry's reputation
BMJ 2005 May 28;330:1229
http://bmj.bmjjournals.com/cgi/content/full/330/7502/1229-a
HSL1724
Burton B.
Pfizer Australia is fined for misleading promotion of celecoxib
BMJ 2005 May 28;330:1230
http://bmj.bmjjournals.com/cgi/content/full/330/7502/1230-b
HSL1872
Dabade G.
Remembering a health campaigner
Deccan Herald 2005 May 23
HSL1782
Allen L.
Fee rise will hit vitamins, medicines
The Financial Review 2005 May 10
HSL1865
Connolly C.
Pentagon to Drop Nexium From Its List Of Covered Drugs for Military Personnel 'Purple Pill' Nexium the First to Be Cut
The Washington Post 2005 May 8
HSL1775
Appleby J.
Merck's marketing of Vioxx called misleading
USA TODAY 2005 May 6
http://www.usatoday.com/printedition/money/20050506/vioxx06.art.htm
HSL4251
Longstaff C, Thelwell C, Whitton C.
The poor quality of streptokinase products in use in developing countries.
J Thromb Haemost 2005 May 01;3(5):1092-3
Link to source with long URL
HSL5451
Wurm P, De Caestecker J.
Emerging drugs for gastro-oesophageal reflux disease.
Expert Opin Emerg Drugs 2005 May 01;10(2):457-71
http://www.expertopin.com/doi/abs/10.1517/14728214.10.2.457
HSL5459
Litten RZ, Fertig J, Mattson M, Egli M.
Development of medications for alcohol use disorders: recent advances and ongoing challenges.
Expert Opin Emerg Drugs 2005 May 01;10(2):323-43
http://www.expertopin.com/doi/abs/10.1517/14728214.10.2.323
HSL2470
McMullin ST, Lonergan TP, Rynearson CS.
Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care.
J Manag Care Pharm 2005 May;11(4):322-32
Nil
HSL1979
Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P.
Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial.
JAMA 2005 Apr 27;293(16):1995-2002
http://jama.ama-assn.org/cgi/content/full/293/16/1995
HSL1876
Pringle E.
Bush-Backed Drug Marketing Schemes
The Sierra Time 2005 Apr 26
HSL853
Carlisle W.
What Went Wrong with Vioxx?
Radio National (Australian Broadcasting Commission) 2005 Apr 10
http://www.abc.net.au/rn/talks/bbing/stories/s1343699.htm
HSL5685
Manchester A.
Counterfeit medicines kill.
Nurs N Z 2005 Apr 01;11(3):10
HSL2478
De Conno F, Ripamonti C, Brunelli C.
Opioid purchases and expenditure in nine western European countries: are we killing off morphine?
Palliat Med. 2005 Apr;19(3):179-84
Link to source with long URL
HSL2387
Kerridge I, Maguire J, Newby D, McNeill PM, Henry D, Hill S, Day R, Macdonald G, Stokes B, Henderson K.
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
Intern Med J 2005 Apr;35(4):206-10
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1444-0903.2004.00799.x
HSL2129
Stanley AG, Jackson D, Barnett DB.
The teaching of drug development to medical students: collaboration between the pharmaceutical industry and medical school.
Br J Clin Pharmacol 2005 Apr;59(4):464-74
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2125.2005.02374.x
HSL5093
Faunce TS, Tomossy GF.
The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
Monash Bioeth Rev 2005 Apr;24(2):38-42
HSL5876
Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, Sam J, Haynes RB.
Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review.
JAMA 2005 Mar 9;293(10):1223-38
http://jama.ama-assn.org/cgi/content/full/293/10/1223
HSL5885
Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL.
Role of computerized physician order entry systems in facilitating medication errors.
JAMA 2005 Mar 9;293(10):1197-203
http://jama.ama-assn.org/cgi/content/full/293/10/1197
HSL5470
Curtiss FR.
Evidence-based medicine: United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market.
J Manag Care Pharm 2005 Mar 01;11(2):176-8
HSL6576
Menighan TE.
Systems-based approach to risk management.
J Am Pharm Assoc (Wash DC) 2005 Mar-Apr 01;45(2):116
HSL1168
Raven M, Rogers W, Jureidini J.
Partnerships between academic psychiatry and the pharmaceutical industry.
Australas Psychiatry 2005 Mar;13(1):83-4
Link to source with long URL
HSL5396
Shatin D, Gardner JS, Stergachis A, Blough D, Graham D.
Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants.
Pharmacoepidemiol Drug Saf 2005 Mar;14(3):149-54
Link to source with long URL
HSL5893
Nikles CJ, Clavarino AM, Del Mar CB.
Using n-of-1 trials as a clinical tool to improve prescribing.
Br J Gen Pract 2005 Mar;55(512):175-80
Link to source with long URL
HSL1890
Mansfield PR.
Beliefs and plans of GP registrars before and after a 90 minute talk about drug promotion
Unpublished 2005 Feb 25
HSL1218
Lexchin J.
Prescribing errors
CMAJ 2005 Jan 18;172(2)
http://www.cmaj.ca/cgi/content/full/172/2/229
HSL2383
Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1;330(7481):5-6
http://bmj.bmjjournals.com/cgi/content/full/330/7481/5
HSL5468
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar;51(1):13-6
Link to source with long URL
HSL1931
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum;29(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215
HSL2715
Muijrers P, Grol R., Sijbrandij J, Janknegt R., Knottnerus J
Differences in prescribing between general practitioners.
Unpublished 2005
Nil
HSL5079
Christenson V.
Drug companies offer major discounts to uninsured.
J Law Med Ethics 2005 Summer;33(2):399-403
HSL5245
Abrahams E, Ginsburg GS, Silver M.
The Personalized Medicine Coalition: goals and strategies.
Am J Pharmacogenomics 2005;5(6):345-55
HSL5913
Regnier K, Kopelow M, Lane D, Alden E.
Accreditation for learning and change: quality and improvement as the outcome.
J Contin Educ Health Prof 2005 Sum;25(3):174-82
Link to source with long URL
HSL5983
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005;22(4):73-107
HSL6132
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html
HSL6407
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005;28(6):495-512
HSL2
Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18;329(7480):1487-8
Link to source with long URL
HSL2389
Scott T, Stanford N, Thompson DR.
Killing me softly: myth in pharmaceutical advertising.
BMJ 2004 Dec 18;329(7480):1484-7
Link to source with long URL
HSL2214
Fitzgerald MA.
Appropriate antibiotic prescribing. Guidance for the use of drug samples
Adv Nurse Pract. 2004 Dec 01;12(12):18-22
HSL5844
Muijrers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA.
Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners.
Eur J Clin Pharmacol 2004 Dec 01;60(10):739-46
Link to source with long URL
HSL486
Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter;4(1):1-4
Nil
HSL1897
Douglas KM, Sutton RM.
Right about others, wrong about ourselves? Actual and perceived self-other differences in resistance to persuasion
Br J Soc Psychol 2004 Dec;43(Pt 4):585-603
Link to source with long URL
HSL1927
Food and Drug Administration, HHS.
Drug labeling; sodium labeling for over-the-counter drugs.
Federal Register 2004 Nov 29;69(228)
Link to source with long URL
HSL2143
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school.
Acad Med. 2004 Nov;79(11):1041-5. 2004 Nov 01;79(11):1041-5
http://www.academicmedicine.org/cgi/content/full/79/11/1041
HSL5960
Dybdahl T, Andersen M, Sondergaard J, Kragstrup J, Kristiansen IS.
Does the early adopter of drugs exist ? A population-based study of general practitioners' prescribing of new drugs.
Eur J Clin Pharmacol 2004 Nov 01;60(9):667-72
Link to source with long URL
HSL487
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT
HSL2210
Huh J, Cude BJ.
Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
J Health Commun 2004 Nov-Dec;9(6):529-40
Link to source with long URL
HSL500
Sweet M.
Doctors and drug companies are locked in 'vicious circle'.
BMJ 2004 Oct 30;329(7473):998
http://bmj.bmjjournals.com/cgi/content/full/329/7473/998
HSL6018
Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30;329
http://bmj.bmjjournals.com/cgi/eletters/329/7473/998
HSL5255
Bensley RJ, Mercer N, Brusk JJ, Underhile R, Rivas J, Anderson J, Kelleher D, Lupella M, de Jager AC.
The eHealth Behavior Management Model: a stage-based approach to behavior change and management.
Prev Chronic Dis 2004 Oct;1(4):A14
Link to source with long URL
HSL5870
Elliott C.
Pharma goes to the laundry: Public relations and the business of medical education.
Hastings Cent Rep 2004 Sep-Oct 01;34(5):18-23
HSL2091
Andrews E, Dombeck M.
The role of scientific evidence of risks and benefits in determining risk management policies for medications.
Pharmacoepidemiol Drug Saf 2004 Sep;13(9):599-608
http://www3.interscience.wiley.com/cgi-bin/abstract/105560406/ABSTRACT
HSL1889
Mansfield PR.
A 5 minute read re drug promotion: RCT
Poster presented at 8th World Congress on Clinical Pharmacology & Therapeutics (CPT2004) Brisbane 2004 Aug 1-6
HSL2079
Caudill-Slosberg MA, Schwartz LM, Woloshin S.
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000.
Pain 2004 Jun;109(3):514-9
http://linkinghub.elsevier.com/retrieve/pii/S0304395904001307
HSL1351
Watkins RS, Kimberly J Jr.
What residents don't know about physician-pharmaceutical industry interactions.
Acad Med 2004 May;79(5):432-7
http://www.academicmedicine.org/cgi/content/full/79/5/432
HSL1368
Sorensen TD, Song J, Westberg SM.
The limitation of good intentions: prescribing medications for the uninsured.
J Health Care Poor Underserved 2004 May;15(2):152-60
HSL2082
Brieger WR, Osamor PE, Salami KK, Oladepo O, Otusanya SA.
Interactions between patent medicine vendors and customers in urban and rural Nigeria.
Health Policy Plan 2004 May;19(3):177-82
http://heapol.oxfordjournals.org/cgi/reprint/19/3/177
HSL251
Charatan F.
Drug company raises US price of AIDS drug five-fold.
BMJ 2004 Apr 24;328(7446):974
http://bmj.bmjjournals.com/cgi/content/full/328/7446/974-a
HSL253
Tanne JH.
US consumer group names
BMJ 2004 Apr 24;328(7446):975
http://bmj.bmjjournals.com/cgi/content/full/328/7446/975-c
HSL1663
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
Lancet 2004 Apr 24;363(9418):1341-5
http://linkinghub.elsevier.com/retrieve/pii/S0140673604160431
HSL257
Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN.
The ethics of pharmaceutical industry relationships with medical students.
Med J Aust 2004 Apr 19;180(8):411-4
http://www.mja.com.au/public/issues/180_08_190404/rog10715_fm.html
HSL2083
Breen KJ.
The medical profession and the pharmaceutical industry: when will we open our eyes?
Med J Aust 2004 Apr 19;180(8):409-10
http://www.mja.com.au/public/issues/180_08_190404/bre10055_fm.html
HSL258
Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL.
Efficacy and safety of antidepressants for children and adolescents.
BMJ 2004 Apr 10;328(7444):879-83
http://bmj.com/cgi/content/full/328/7444/879
HSL245
Gulhati CM.
Marketing of medicines in India.
BMJ 2004 Apr 3;328(7443):778-9
http://bmj.bmjjournals.com/cgi/content/full/328/7443/778
HSL260
Moynihan R.
Drug spending in North America rose by 11% in 2003.
BMJ 2004 Mar 27;328(7442):727
http://bmj.bmjjournals.com/cgi/content/full/328/7442/727
HSL263
Meek C.
Spanish journal wins lawsuit over COX-2 drug editorial.
CMAJ 2004 Mar 16;170(6):940
http://http://www.cmaj.ca/cgi/content/full/170/6/940-a
HSL5847
Sweet M.
Development of strategies to encourage adoption of best evidence into practice in Australia: workshop overview.
Med J Aust 2004 Mar 15;180(6)
http://www.mja.com.au/public/issues/180_06_150304/swe10882_fm.html
HSL267
Slutsky AS, Lavery JV.
Data safety and monitoring boards.
N Engl J Med 2004 Mar 11;350(11):1143-7
http://content.nejm.org/cgi/content/full/350/11/1143
HSL388
Pugh T
Medicare plan cost estimates ordered withheld
Knight Ridder Newspapers 2004 Mar 11
Nil
HSL266
Zoutman DE, Ford BD, Bassili AR.
The confidentiality of patient and physician information in pharmacy prescription records.
CMAJ 2004 Mar 2;170(5):815-6
http://www.cmaj.ca/cgi/content/full/170/5/815
HSL5845
Sanson-Fisher RW, Grimshaw JM, Eccles MP.
The science of changing providers' behaviour: the missing link in evidence-based practice.
Med J Aust 2004 Mar 1;180(5):205-6
http://www.mja.com.au/public/issues/180_05_010304/san10013_fm.html
HSL5860
Berger RG, Kichak JP.
Computerized physician order entry: helpful or harmful?
J Am Med Inform Assoc 2004 Mar-Apr 01;11(2):100-3
http://www.jamia.org/cgi/content/full/11/2/100
HSL283
McPherson K, Hemminki E.
Synthesising licensing data to assess drug safety.
BMJ 2004 Feb 28;328(7438):518-20
http://bmj.bmjjournals.com/cgi/content/full/328/7438/518
HSL276
Garland EJ.
Facing the evidence: antidepressant treatment in children and adolescents.
CMAJ 2004 Feb 17;170(4):489-91
http://www.cmaj.ca/cgi/content/full/170/4/489
HSL296
Goulding MR.
Inappropriate medication prescribing for elderly ambulatory care patients.
Arch Intern Med 2004 Feb 9;164(3):305-12
http://archinte.ama-assn.org/cgi/content/full/164/3/305
HSL297
Gibson L.
Spanish drug editor wins case brought by Merck, Sharp Dohme.
BMJ 2004 Feb 7;328(7435):307
http://bmj.bmjjournals.com/cgi/content/full/328/7435/307-b
HSL298
Moynihan R.
FDA advisory panel calls for suicide warnings over new antidepressants.
BMJ 2004 Feb 7;328(7435):303
http://bmj.bmjjournals.com/cgi/content/full/328/7435/303-a
HSL299
Moynihan R.
Drug company targets US state health officials.
BMJ 2004 Feb 7;328(7435):306
http://bmj.bmjjournals.com/cgi/content/full/328/7435/306
HSL300
Mello MM, Studdert DM, Brennan TA.
The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
N Engl J Med 2004 Feb 5;350(6):608-13
http://content.nejm.org/cgi/content/full/350/6/608
HSL301
Morgan S.
Sources of variation in provincial drug spending.
CMAJ 2004 Feb 3;170(3):329-30
http://www.cmaj.ca/cgi/content/full/170/3/329
HSL671
Schafer A.
Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy.
J Med Ethics 2004 Feb;30(1):8-24
http://jme.bmjjournals.com/cgi/content/full/30/1/8
HSL1371
Drug costs: research and development costs: the great illusion
Prescrire Int 2004 Feb;13(69):32-6
HSL5122
Moss F, Thomson R.
A new structure for quality improvement reports.
Qual Saf Health Care 2004 Feb;13(1):6-7
Link to source with long URL
HSL303
Lee TH.
N Engl J Med 2004 Jan 15;350(3):211-2
http://content.nejm.org/cgi/content/full/350/3/211
HSL2724
Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J.
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
JAMA 2004 Jan 7;291(1):54-62
http://jama.ama-assn.org/cgi/content/full/291/1/54
HSL1340
Woloshin S, Schwartz LM, Welch HG.
The value of benefit data in direct-to-consumer drug ads.
Health Aff (Millwood) 2004 Jan-Jun;Suppl Web Exclusives:W4-234-45
http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.234v1
HSL5857
Bell DS, Cretin S, Marken RS, Landman AB.
A conceptual framework for evaluating outpatient electronic prescribing systems based on their functional capabilities.
J Am Med Inform Assoc 2004 Jan-Feb 01;11(1):60-70
http://www.jamia.org/cgi/content/full/11/1/60
HSL489
Svensson S, Mansfield PR.
Escitalopram: superior to citalopram or a chiral chimera?
Psychother Psychosom 2004 Jan-Feb;73(1):10-6
Link to source with long URL
HSL490
Mansfield P, Henry D, Tonkin A.
Single-enantiomer drugs: elegant science, disappointing effects.
Clin Pharmacokinet 2004;43(5):287-90
Link to source with long URL
HSL1924
Collins K.
Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.
Perspect Biol Med 2004 Win;47(1):100-9
Link to source with long URL
HSL2090
Baker D.
A free market solution for prescription drug crises.
Int J Health Serv 2004;34(3):517-26
HSL5912
Poon EG, Blumenthal D, Jaggi T, Honour MM, Bates DW, Kaushal R.
Overcoming barriers to adopting and implementing computerized physician order entry systems in U.S Hospitals
Health Aff. 2004;23:184-190
http://content.healthaffairs.org/cgi/content/full/23/4/184
HSL6
Gardiner H.
States Try to Limit Drugs in Medicaid, but Makers Resist
New York Times 2003 Dec 18
Nil
HSL1413
Mansfield PR.
Healthy Skepticism's new AdWatch: understanding drug promotion.
Med J Aust 2003 Dec 1-15;179(11-12):644-5
http://www.mja.com.au/public/issues/179_11_011203/man10667_fm.html
HSL1037
Katz D, Mansfield P, Goodman R, Tiefer L, Merz J.
Psychological aspects of gifts from drug companies.
JAMA 2003 Nov 12;290(18):2404-5
http://jama.ama-assn.org/cgi/content/full/290/18/2404-b
HSL2241
Millstein LG.
Prescription drug advertising: is it a driving force on drug pricing?
N C Med J 2003 Nov-Dec;64(6):289-91
HSL6022
Mansfield PR.
Drug company sponsorship would endanger health care improvement
BMJ 2003 Oct 17;327
http://bmj.bmjjournals.com/cgi/eletters/327/7420/924
HSL2232
Peebles ME.
And now, a word from our sponsor.
Harv Bus Rev 2003 Oct;81(10):31-5
HSL2719
Prosser H, Walley T.
New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach.
Fam Pract 2003 Oct;20(5):583-91
http://fampra.oxfordjournals.org/cgi/content/full/20/5/583
HSL2240
Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA.
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
CMAJ. 2003 Sep 2;169(5):405-12
http://www.cmaj.ca/cgi/content/full/169/5/405
HSL5873
Finkelstein JA, Stille C, Nordin J, Davis R, Raebel MA, Roblin D, Go AS, Smith D, Johnson CC, Kleinman K, Chan KA, Platt R.
Reduction in antibiotic use among US children, 1996-2000.
Pediatrics 2003 Sep 01;112(3)
http://pediatrics.aappublications.org/cgi/content/full/112/3/620
HSL1454
Coleman B.
Producing an information leaflet to help patients access high quality drug information on the Internet: a local study.
Health Info Libr J 2003 Sep;20(3):160-71
Link to source with long URL
HSL1458
Cathebras P.
[Doctor Knock lives at Wall Street. The new targets of pharmaceutical industry]
Rev Med Interne 2003 Aug;24(8):538-41
HSL2725
Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J.
Physician and practice characteristics associated with the early utilization of new prescription drugs.
Med Care 2003 Aug;41(8):895-908
Link to source with long URL
HSL2426
Dana J, Loewenstein G.
A social science perspective on gifts to physicians from industry.
JAMA 2003 Jul 9;290(2):252-5
http://jama.ama-assn.org/cgi/content/full/290/2/252
HSL5886
Kuperman GJ, Gibson RF.
Computer physician order entry: benefits, costs, and issues.
Ann Intern Med 2003 Jul 1;139(1):31-9
http://www.annals.org/cgi/reprint/139/1/31.pdf
HSL5882
Kaushal R, Shojania KG, Bates DW.
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review.
Arch Intern Med 2003 Jun 23;163(12):1409-16
http://archinte.ama-assn.org/cgi/content/full/163/12/1409
HSL566
Mansfield PR.
Bribes for doctors: a gift for bioethicists?
Am J Bioeth 2003 Summer;3(3):47-8
Nil
HSL2524
Burton B, Rowell A.
Unhealthy spin.
BMJ 2003 May 31;326(7400):1205-7
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1205
HSL1415
Ma J, Stafford R, Cockburn I, Finkelstein S.
A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998
Clin Ther 2003 May;25(5):1503-17
Link to source with long URL
HSL1425
Kocs D, Fendrick AM.
Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Am J Manag Care 2003 May;9(5):393-400
http://www.ajmc.com/files/articlefiles/AJMC2003mayKocsCPE393-402.pdf
HSL1459
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP.
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
CMAJ 2003 Apr 29;168(9):1133-7
http://www.cmaj.ca/cgi/content/full/168/9/1133
HSL1453
Cooper RJ, Schriger DL, Wallace RC, Mikulich VJ, Wilkes MS.
The quantity and quality of scientific graphs in pharmaceutical advertisements.
J Gen Intern Med 2003 Apr;18(4):294-7
Link to source with long URL
HSL2100
Zimmerman HM.
Rx for compliance. How the new PhRMA code on permissible pharmaceutical marketing practices affects your organization
MGMA Connex. 2003 Feb 01;3(2):54-7, 1.
HSL2441
Prosser H, Almond S, Walley T.
Influences on GPs' decision to prescribe new drugs-the importance of who says what.
Fam Pract 2003 Feb;20(1):61-8
http://fampra.oxfordjournals.org/cgi/content/full/20/1/61
HSL1383
Villanueva P, Peiro S, Librero J, Pereiro I.
Accuracy of pharmaceutical advertisements in medical journals.
Lancet 2003 Jan 4;361(9351):27-32
http://linkinghub.elsevier.com/retrieve/pii/S0140673603121186
HSL5957
Helgason T, Tomasson K, Zoega T.
[Prevalence and distribution of antidepressant, anxiolytic and hypnotic use in 2001].
Laeknabladid 2003 Jan 01;89(1):15-22
HSL1446
Dubois RW.
Pharmaceutical promotion: don't throw the baby out with the bathwater.
Health Aff (Millwood) 2003 Jan-Jun;Suppl
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.96v1
HSL1472
Batchlor E, Laouri M.
Pharmaceutical promotion, advertising, and consumers.
Health Aff (Millwood) 2003 Jan-Jun;Suppl
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.109v1
HSL2108
Vogel RJ, Ramachandran S, Zachry WM.
A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals.
Clin Ther 2003 Jan;25(1):309-29
Link to source with long URL
HSL302
Katz D, Caplan AL, Merz JF.
All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving.
Am J Bioeth 2003;3(3):39-46
Link to source with long URL
HSL1414
Manima A.
Ethical issues in palliative care: considerations.
J Pain Palliat Care Pharmacother 2003;17(3-4):141-9;
HSL1460
Carter T.
Pfizer and its competitive marketing challenges.
J Hosp Mark Public Relations 2003;14(2):85-97
HSL2396
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books; 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html
HSL6145
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003;81(5):367-72
Link to source with long URL
HSL2139
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4;:A1,
HSL2902
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Quality of global e-pharmacies: can we safeguard consumers?
Eur J Clin Pharmacol 2002 Dec;58(9):567-72
Link to source with long URL
HSL2876
Dukes MN.
Accountability of the pharmaceutical industry.
Lancet 2002 Nov 23;360(9346):1682-4
http://linkinghub.elsevier.com/retrieve/pii/S0140673602115996
HSL2866
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16;360(9345):1590-5
Link to source with long URL
HSL556
Brodie M, Levitt L.
Drug advertising: the right or wrong prescription for our ailments?
Nat Rev Drug Discov 2002 Nov;1(11):916-20
Link to source with long URL
HSL2899
Boltri JM, Gordon ER, Vogel RL.
Effect of antihypertensive samples on physician prescribing patterns.
Fam Med 2002 Nov-Dec;34(10):729-31
Link to source with long URL
HSL2257
Sweet M.
Conference promotion in the media: serving whose interests?
Med J Aust 2002 Oct 7;177(7):341-2
http://www.mja.com.au/public/issues/177_07_071002/swe10463_fm.html
HSL1420
Braithwaite J.
Restorative Justice and Responsive Regulation
Oxford: Oxford University Press; 2002
http://www.oup.co.uk/isbn/0-19-515839-3
HSL2568
Maitland I.
Priceless goods: how should life-saving drugs be priced?
Bus Ethics Q 2002 Oct;12(4):451-80
Link to source with long URL
HSL2217
Brotons C, Moral I, Ribera A, Cascant P, Iglesias M, Permanyer-Miralda G, Ferreira Gonzalez I, Soler-Soler J.
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention.]
Rev Esp Cardiol 2002 Oct;55(10):1042-51
Link to source with long URL
HSL2610
Loke TW, Koh FC, Ward JE.
Pharmaceutical advertisement claims in Australian medical publications.
Med J Aust 2002 Sep 16;177(6):291-3
http://www.mja.com.au/public/issues/177_06_160902/lok10004_fm.html
HSL2448
Fugh-Berman A, Pearson C.
The overselling of hormone replacement therapy.
Pharmacotherapy 2002 Sep;22(9):1205-8
HSL1893
Sagarin BJ, Cialdini RB, Rice WE, Serna SB.
Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion.
J Pers Soc Psychol 2002 Sep;83(3):526-41
http://content.apa.org/journals/psp/83/3/526
HSL2261
Stewart KA, Neumann PJ.
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Value Health 2002 Sep-Oct;5(5):389-96
Link to source with long URL
HSL2883
Cox ER, Henderson RR.
Prescription use behavior among medicare beneficiaries with capped prescription benefits.
J Manag Care Pharm 2002 Sep-Oct;8(5):360-4
Link to source with long URL
HSL2258
Sweet M.
Australian media raises alarm over meningitis
BMJ 2002 Aug 14;325:604
http://bmj.com/cgi/content/full/325/7364/604
HSL5867
Doolan DF, Bates DW.
Computerized physician order entry systems in hospitals: mandates and incentives.
Health Aff (Millwood) 2002 Jul-Aug 01;21(4):180-8
http://content.healthaffairs.org/cgi/reprint/21/4/180
HSL2292
Ripamonti C, Bianchi M.
The use of methadone for cancer pain.
Hematol Oncol Clin North Am 2002 Jun;16(3):543-55
HSL2298
Pinkus RL.
From Lydia Pinkham to Bob Dole: what the changing face of direct-to-consumer drug advertising reveals about the professionalism of medicine.
Kennedy Inst Ethics J 2002 Jun;12(2):141-58
Link to source with long URL
HSL2437
Hall KH.
Reviewing intuitive decision-making and uncertainty: the implications for medical education.
Med Educ 2002 Mar;36(3):216-24
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2923.2002.01140.x
HSL3097
Questions of interest
Canadian Medical Association Journal 2002 Feb 19;166(4):413
HSL2868
Haugh R, Thrall TH, Scalise D.
Prescription for concern.
Hosp Health Netw 2002 Feb;76(2):44-9
Link to source with long URL
HSL2903
Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb;2(1):6-11
Link to source with long URL
HSL1483
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA.
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
Am J Health Syst Pharm 2002 Jan 1;59(1):42-9
http://www.ajhp.org/cgi/reprint/59/1/42
HSL113
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002;324:278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
HSL117
Choudhry NK, Stelfox HT, Detsky AS
Relationships between authors of clinical practice guidelines and the pharmaceutical industry
JAMA 2002;287:612-617
http://jama.ama-assn.org/cgi/content/full/287/5/612
HSL2246
Vlasov VV.
[Emerging problems of medical ethics in Russia: medical practice and research]
Kardiologiia. 2002;42(5):81-4. 2002;42(5):81-4
Link to source with long URL
HSL2302
Pavenik N.
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Rand J Econ 2002 Aut;33(3):469-87
Link to source with long URL
HSL2895
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20
Link to source with long URL
HSL2905
Baird PA.
Identification of genetic susceptibility to common diseases: the case for regulation.
Perspect Biol Med 2002 Fal;45(4):516-28
Link to source with long URL
HSL4285
Is Yasmin a "truly different" pill?
Drug Ther Bull 2002;40(8):57-9
Link to source with long URL
HSL119
Wilkes MS, Hoffman JR.
An innovative approach to educating medical students about pharmaceutical promotion.
Acad Med 2001 Dec;76(12):1271-1277
http://www.academicmedicine.org/cgi/content/full/76/12/1271
HSL5921
Steinman MA, Sands LP, Covinsky KE.
Self-restriction of medications due to cost in seniors without prescription coverage.
J Gen Intern Med 2001 Dec;16(12):793-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.2001.10412.x
HSL2382
Sackett DL.
Why randomized controlled trials fail but needn't: 2 Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!).
CMAJ 2001 Oct 30;165(9):1226-37
http://www.cmaj.ca/cgi/content/full/165/9/1226
HSL2510
McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS.
Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior.
JAMA 2001 Oct 24-31;286(16):1994-9
http://jama.ama-assn.org/cgi/content/full/286/16/1994
HSL2720
Schwartz TL, Kuhles DJ 2nd, Wade M, Masand PS.
Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits.
Ann Clin Psychiatry 2001 Sep;13(3):159-62
Link to source with long URL
HSL2947
Reidenberg , M .
Releasing the grip of big pharma (1st of 3 letters)
Lancet 2001 Aug 25;358:664
HSL129
Jones MI, Greenfield SM, Bradley CP.
Prescribing new drugs: qualitative study of influences on consultants and general practitioners
BMJ 2001;323:378-384
http://bmj.bmjjournals.com/cgi/content/full/323/7309/378
HSL2695
Gonul F, Carter F, Petrova E, Srinivasan K.
Promotion of Prescription Drugs and its impact on Physicians’ Choice Behaviour
Journal of Marketing 2001 Jul;65:79-90
Nil
HSL8520
Kinard ME.
Key components responsible for increasing drug costs
ASHP Annual Meeting 2001 Jun;58
HSL8521
Jackimiec JM.
Communicating utilization and critical issues to health providers
ASHP Annual Meeting 2001 Jun;58
HSL8523
Kostek NE.
Use of pharmacy carve-outs as a managed care strategy to recover pharmacy costs and generate revenues in an acute care setting
ASHP Annual Meeting 2001 Jun;58
HSL5851
Bailar JC 3rd.
The powerful placebo and the Wizard of Oz.
N Engl J Med 2001 May 24;344(21):1630-2
http://content.nejm.org/cgi/content/extract/344/21/1630
HSL2682
Zitner D.
Prescription data
Canadian Medical Association Journal 2001 May 15;164(10):1408-1409
HSL2697
Short , S .
Prescription data
CMAG 2001 May 15;164(10):1408
HSL2919
Sukkari S, Sasich , L .
Cisapride and patient information leaflets (1st of 4 letters)
Canadian Medical Association Journal 2001 May 1;164(9):1276-1278
HSL2981
Arnott W.
Cisapride and patient information leaflets (2nd of 4 letters)
Canadian Medical Association Journal 2001 May 1;164(9):1278
HSL121
Stout E.
Doctoring sales
Sales & Marketing Management 2001 May:52-60
Nil
HSL2741
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb;49:266-73
HSL8530
Mehl B, Santell J.
Projecting future drug expenditures--2001.
Am J Health Syst Pharm 2001 Jan 15;58(2):125-33
http://www.ajhp.org/cgi/reprint/58/2/125
HSL8531
Weiner S, Dischler J, Horvitz C.
Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program.
Am J Health Syst Pharm 2001 Jan 15;58(2):146-50
http://www.ajhp.org/cgi/reprint/58/2/146
HSL118
Woloshin S, Schwartz LM, Tremmel J, Welch HG
Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?
Lancet 2001;358:1141-1146
http://linkinghub.elsevier.com/retrieve/pii/S0140673601062547
HSL122
Sigworth SK, Nettleman MD, Cohen GM.
Pharmaceutical branding of resident physicians
JAMA 2001;JAMA:1024-1025
http://jama.ama-assn.org/cgi/content/full/286/9/1024-a
HSL2405
Ainslie G.
Breakdown of Will
Cambridge: Cambridge University Press; 2001
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521596947
HSL2962
Meek C.
2001
www.rpsgb.org.uk/pdfs/dtcarep.pdf
HSL1659
Jureidini JN.
Epidemic of schizophrenia in children or inappropriate prescribing?
Med J Aust 2000 Nov 20;173(10):555-6
HSL350
Freemantle N, Anderson IM, Young P.
Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.
Br J Psychiatry 2000 Oct;177:292-302
http://bjp.rcpsych.org/cgi/content/full/177/4/292
HSL2459
Norman GR.
The epistemology of clinical reasoning: perspectives from philosophy, psychology, and neuroscience.
Acad Med 2000 Oct;75(10)
Link to source with long URL
HSL339
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB.
Coverage by the news media of the benefits and risks of medications.
N Engl J Med 2000 Jun 1;342(22):1645-50
http://content.nejm.org/cgi/content/full/342/22/1645
HSL2450
Hemminki E, McPherson K.
Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.
Lancet 2000 Feb 12;355(9203):566-9
http://linkinghub.elsevier.com/retrieve/pii/S0140673699034327
HSL2406
Sutherland M, Sylvester AK.
Advertising and the Mind of the Consumer 2nd Ed: What works, what doesn't, and why.
Sydney: Allen & Unwin; 2000
Link to source with long URL
HSL1766
Cialdini RB.
Influence: Science and Practice 4th Edn
New York: Allyn & Bacon; 2000
http://www.ablongman.com/catalog/academic/product/0,1144,0321011473,00.html
HSL2390
Braithwaite J, Drahos P.
Global business regulation.
Cambridge: Cambridge University Press; 2000
http://www.cambridge.org/uk/catalogue/catalogue.asp?isbn=0521784999
HSL2164
Pearson S, Smith AJ, Rolfe IE, Moulds RF, Shenfield GM.
Intern Prescribing for Common Clinical Conditions.
Adv Health Sci Educ Theory Pract 2000;5(2):141-150
Link to source with long URL
HSL2609
Roughead L, Semple S, Vitry A.
The Value of Pharmacist Professional Services in the Community: A systematic review of the literature 1990-2002
2000
HSL8519
Letendre W, Jackson R.
Marketing your prescription compounding practice. Part 3
International Journal of Pharmaceutical Compounding 2000;4(3):199-202
HSL2516
Wynia MK, Latham SR, Kao AC, Berg JW, Emanuel LL.
Medical professionalism in society.
N Engl J Med 1999 Nov 18;341(21):1612-6
http://content.nejm.org/cgi/content/extract/341/21/1612
HSL2158
Jackson C, Mcguire T, Dommers E, Nyst P.
A GP prescribing educational intervention involving a medication panel.
Aust Fam Physician 1999 Nov;28(11):1191-5
HSL2159
Slawson DC, Shaughnessy AF.
Teaching information mastery: creating informed consumers of medical information.
J Am Board Fam Pract 1999 Nov-Dec;12(6):444-9
HSL5855
Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L.
The impact of computerized physician order entry on medication error prevention.
J Am Med Inform Assoc 1999 Jul-Aug 01;6(4):313-21
http://www.jamia.org/cgi/content/full/6/4/313
HSL2436
Elstein AS.
Heuristics and biases: selected errors in clinical reasoning.
Acad Med 1999 Jul;74(7):791-4
Nil
HSL2140
Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar;32(2):93-6
HSL2692
Dolovich L, Levine M, Tarajos R, Duku E.
Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.
Drug Information Journal 1999;33(4):1067-1077
Link to source with long URL
HSL513
Jefferson BK.
Cal Ripken, Jr and Prinivil
;339(27):2024-5. N Engl J Med 1998 Dec 31;339(27):2024
Link to source with long URL
HSL550
Collier J.
Patient-information leaflets and prescriber competence.
Lancet 1998 Nov 28;352(9142):1724
Link to source with long URL
HSL532
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov;44:2376
Nil
HSL5854
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.
JAMA 1998 Oct 21;280(15):1311-6
http://jama.ama-assn.org/cgi/content/full/280/15/1311
HSL540
Kamat VR, Nichter M.
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India.
Soc Sci Med 1998 Sep;47(6):779-94
Link to source with long URL
HSL2462
Frances A, Kahn D, Carpenter D, Frances C, Docherty J.
A new method of developing expert consensus practice guidelines.
Am J Manag Care 1998 Jul;4(7):1023-9
http://www.ajmc.com/Article.cfm?Menu=1&ID=1662
HSL517
Roughead EE, Harvey KJ, Gilbert AL.
Commercial detailing techniques used by pharmaceutical representatives to influence prescribing.
Aust N Z J Med 1998 Jun;28(3):306-10
Nil
HSL549
Day R.
Pharmaceutical company promotion: striking a balance.
Aust N Z J Med 1998 Jun;28(3):291-3
Nil
HSL5918
Schiff GD, Rucker TD.
Computerized prescribing: building the electronic infrastructure for better medication usage.
JAMA 1998 Apr 1;279(13):1024-9
http://jama.ama-assn.org/cgi/content/full/279/13/1024
HSL5872
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP.
A computer-assisted management program for antibiotics and other antiinfective agents.
N Engl J Med 1998 Jan 22;338(4):232-8
http://content.nejm.org/cgi/content/abstract/338/4/232
HSL548
Stelfox HT, Chua G, O'Rourke K, Detsky AS.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jan 8;338(2):101-6
http://content.nejm.org/cgi/content/abstract/338/2/101
HSL519
Roughead EE, Gilbert AL, Harvey KJ.
Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?
Int J Health Serv 1998;28(2):269-79
Nil
HSL502
Wagner E.
Ghostwriting
The Lancet 1998;351:1741
Nil
HSL533
Lexchin J.
Improving the appropriateness of physician prescribing.
Int J Health Serv 1998;28(2):253-67
Nil
HSL5911
Pizor , TC .
A medical publisher reminds us: don't forget the gatekeepers
Med Mark Media 1998;33:65-67
HSL2449
Hemminki E, McPherson K.
Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.
BMJ 1997 Jul 19;315(7101):149-53
http://bmj.bmjjournals.com/cgi/content/full/315/7101/149
HSL2218
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43:941-5
Nil
HSL672